Evidence map›Paper›PMID 25972406›Full record

ArticleClinical and vaccine immunology : CVI2015

Cross-Reactive Epitopes in Borrelia burgdorferi p66.

Paul M Arnaboldi, Raymond J Dattwyler

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Borrelia surface proteins: new horizons in Lyme disease diagnosis.Applied microbiology and biotechnology · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Allelic Variants ofMicroorganisms · 2022
    Article
  6. Article
  7. Laboratory Diagnosis of Lyme Borreliosis.Clinical microbiology reviews · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paul M ArnaboldiBiopeptides Corp., East Setauket, New York, USA, and Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, USA paul_arnaboldi@nymc.edu.
Raymond J DattwylerBiopeptides Corp., East Setauket, New York, USA, and Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, USA.
New York Medical College · US

Funding

Multi-antigen peptide assay for the serodiagnosis of Lyme diseaseR44AI074092 · NIAID · BIOPEPTIDES, INC. · PI GOMES-SOLECKI, MARIA · 2009 to 2011
$2.0M
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme DiseaseR43AI102435 · NIAID · BIOPEPTIDES, INC. · PI ARNABOLDI, PAUL MICHAEL · 2012 to 2013
$600k
NIAID NIH HHS R43 AI102435NIAID NIH HHS R44 AI074092
6 · The paper itself

Abstract

Epitope mapping of the p66 outer membrane protein of Borrelia burgdorferi revealed that the protein contains numerous cross-reactive linear epitopes recognized by serum antibody in the majority of individuals tested, regardless of Lyme disease history, limiting the usefulness of this antigen in Lyme disease serodiagnostic assays.

Indexed as

Cross ReactionsBacterial ProteinsBorrelia burgdorferiEpitope MappingEpitopes, B-LymphocyteHumansLyme DiseasePorinsSerologic TestsBacterial ProteinsEpitopes, B-LymphocyteOms66 protein, BorreliaPorins

Identifiers

PMID25972406
PMCPMC4478522
OpenAlexW2108354305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.